← Back to Screener
Onconetix, Inc. Common Stock (ONCO)
Price$0.74
Favorite Metrics
Price vs S&P 500 (26W)-104.69%
Price vs S&P 500 (4W)-85.62%
Market Capitalization$512,766
All Metrics
Book Value / Share (Quarterly)$50.53
P/TBV (Annual)0.54x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-31.02
Price vs S&P 500 (YTD)-94.65%
Gross Margin (TTM)77.62%
Net Profit Margin (TTM)-1720.98%
EPS (TTM)$-74.04
10-Day Avg Trading Volume27.17M
EPS Excl Extra (TTM)$-74.04
EPS (Annual)$-74.82
ROI (Annual)-89.00%
Gross Margin (Annual)77.62%
Cash / Share (Quarterly)$16.73
Revenue Growth QoQ (YoY)-57.36%
ROA (Last FY)-56.29%
Revenue Growth TTM (YoY)-67.70%
EBITD / Share (TTM)$-47.91
ROE (5Y Avg)-211.86%
Operating Margin (TTM)-2874.50%
Cash Flow / Share (Annual)$-31.02
P/B Ratio0.03x
P/B Ratio (Quarterly)0.15x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)-5.77x
Net Interest Coverage (TTM)-3.72x
ROA (TTM)-68.04%
EPS Incl Extra (Annual)$-74.82
Current Ratio (Annual)0.66x
Quick Ratio (Quarterly)0.61x
3-Month Avg Trading Volume3.93M
52-Week Price Return-97.08%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$69.53
P/S Ratio (Annual)0.63x
Asset Turnover (Annual)0.03x
52-Week High$74.30
EPS Excl Extra (Annual)$-74.82
26-Week Price Return-95.95%
Quick Ratio (Annual)0.61x
13-Week Price Return-90.69%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.66x
Enterprise Value$-4.708
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1720.91%
Cash / Share (Annual)$16.73
3-Month Return Std Dev206.51%
Net Income / Employee (TTM)$-3
ROE (Last FY)-89.00%
Net Interest Coverage (Annual)0.10x
EPS Basic Excl Extra (Annual)$-74.82
Receivables Turnover (TTM)5.06x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-74.04
ROI (TTM)-117.28%
P/S Ratio (TTM)0.63x
Revenue / Share (Annual)$4.35
Tangible BV / Share (Annual)$347.58
Price vs S&P 500 (52W)-132.18%
Year-to-Date Return-90.51%
5-Day Price Return-7.50%
EPS Normalized (Annual)$-74.82
ROA (5Y Avg)-93.87%
Net Profit Margin (Annual)-1720.98%
Month-to-Date Return-50.34%
EBITD / Share (Annual)$-58.90
Operating Margin (Annual)-2874.50%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-149.88%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-74.04
P/TBV (Quarterly)0.54x
P/B Ratio (Annual)0.15x
Inventory Turnover (TTM)1.70x
Pretax Margin (TTM)-1720.91%
Book Value / Share (Annual)$50.53
Price vs S&P 500 (13W)-93.56%
Beta3.16x
Revenue / Share (TTM)$2.60
ROE (TTM)-187.02%
52-Week Low$0.67
Analyst Recommendations
Feb 2024
Mar 2024
Apr 2024
May 2024
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ONCOOnconetix, Inc. Common Stock | 0.63x | -67.70% | 77.62% | — | $0.74 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Onconetix Inc is a commercial-stage biotechnology company specializing in men's health and oncology solutions. The company markets Entadfi, an FDA-approved once-daily oral therapy for benign prostatic hyperplasia. Beyond its flagship product, Onconetix is developing a pipeline of oncology-focused therapeutics, diagnostics, and clinician services.